Exagen signals $65M-$70M revenue target for 2025 while advancing new biomarker launches
Source: SeekingAlpha
2025-11-04 15:57:15 ET
More on Exagen
- Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
- Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For Now
- Exagen GAAP EPS of -$0.31 misses by $0.15, revenue of $17.24M beats by $0.34M
- Seeking Alpha’s Quant Rating on Exagen
- Historical earnings data for Exagen
Read the full article on Seeking Alpha
For further details see:
Exagen signals $65M–$70M revenue target for 2025 while advancing new biomarker launches
Exagen Inc.
NASDAQ: XGN
XGN Trading
3.08% G/L:
$3.4015 Last:
603,728 Volume:
$3.40 Open:
XGN Latest News
February 24, 2026 09:00:00 am
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
XGN Stock Data
$80,000,739
13,869,817
3.15%
15
N/A
Medical Diagnostics & Screening
Healthcare
US
Vista
